Table 3.
The clinical features of the presymptomatic patients and the completely asymptomatic patients with COVID-19.
| Value |
|||
|---|---|---|---|
| Characteristics | Presymptomatic patients (n = 34) | Completely asymptomatic patients (n = 45) | P value |
| Age | |||
| Median (IQR) (range) | 68.50(49.00,80.50) (16–96 yr) | 55.00(37.50,64.00) (9–85 yr) | 0.002 |
| Distribution -(n, %) | |||
| <18 yr | 1 (2.94) | 1 (2.22) | 0.008 |
| 18–45 yr | 7 (20.59) | 16 (35.56) | |
| 46–65 yr* | 6 (17.65) | 18 (40.00) | |
| ≥66 yr* | 20 (58.82) | 10 (22.22) | |
| Sex(female) (n, %) | 0.135 | ||
| Male | 17 (50.00) | 15 (33.33) | |
| Female | 17 (50.00) | 30 (66.67) | |
| Coexisting disorder (n, %) | |||
| Asthma | 0 (0) | 1 (2.22) | 1.000 |
| Diabetes | 10 (29.41) | 6 (13.33) | 0.078 |
| Hypertension | 15 (44.12) | 2 (4.44) | <0.001 |
| Coronary heart disease | 3 (8.82) | 0 (0) | 0.076 |
| Cerebrovascular disease | 2 (5.88) | 2 (4.44) | 1.000 |
| Chronic renal disease | 3 (8.82) | 0 (0) | 0.076 |
| Cancer | 3 (8.82) | 2 (4.44) | 0.647 |
| Total with≥2 comorbidity | 11 (32.35) | 3 (6.67) | 0.003 |
| Abnormalities on chest CT (n, %) | |||
| Unilateral | 7 (20.59) | 5 (11.11) | 0.185 |
| Bilateral | 25 (73.53) | 35 (77.78) | |
| No abnormalities | 2 (5.88) | 5 (11.11) | |
| Ground-glass opacity | 6 (17.65) | 13 (28.89) | 0.247 |
| Patchy shadowing | 23 (67.65) | 24 (53.33) | 0.199 |
| Interstitial abnormalities | 4 (11.76) | 4 (8.89) | 0.720 |
| Thickening of the adjacent pleura | 6 (17.65) | 5 (11.11) | 0.615 |
| Blood routine test | |||
| Leukocytes (× 10⁹ per L; normal range 3.50–9.50) | 5.50 (60,7.20) | 5.70 (4.75,7.10) | 0.801 |
| Neutrophils (× 10⁹ per L; normal range 1.80–6.30) | 3.25 (2.67,4.81) | 3.42 (2.75,4.41) | 0.972 |
| Lymphocytes (× 10⁹ per L; normal range 1.10–3.20) |
1.58 (1.31,1.95) | 1.69 (1.31,2.12) | 0.461 |
| Monocyte (× 10⁹ per L; normal range 0.10–0.60) | 0.39 (0.28,0.48) | 0.35 (0.27,0.44) | 0.349 |
| Platelets (×10⁹per L; normal range 125.00–350.00) | 204.50 (177.25,237.50) | 213.00 (187.00,250.00) | 0.223 |
| Neutrophil percentage (%; normal range 40.00–75.00) |
62.00 (57.50,66.45) | 59.00 (52.15,67.85) | 0.744 |
| lymphocytes percentage (%; normal range 20.00–50.00) |
29.90 (23.45,33.23) | 30.70 (23.95,36.50) | 0.329 |
| Monocytes percentage (%; normal range 3.00–10.00) |
6.15 (4.88,7.55) | 6.10 (5.15,7.25) | 0.988 |
| Blood biochemistry | |||
| Albumin (g/L; normal range 35.00–52.00) | 37.75 (35.40,39.28) | 40.20 (37.60,41.80) | 0.004 |
| Alanine aminotransferase (U/L; normal range0.00–55.00) |
14.90 (8.50,21.30) | 15.35 (10.30,27.80) | 0.309 |
| Aspartate aminotransferase (U/L; normal range5.00–34.00) |
16.10 (13.80,23.38) | 14.25 (12.10,19.33) | 0.090 |
| Total bilirubin (μmol/L; normal range 0.00–21.00) | 10.70 (6.13,13.55) | 8.80 (7.13,13.95) | 0.592 |
| Blood urea nitrogen (mmol/L; normal range 3.10–8.80) |
4.58 (3.74,6.27) | 4.43 (3.71,5.22) | 0.592 |
| Serum creatinine (μmol/L; normal range 49.00–90.00) |
67.05 (60.05,80.55) | 59.50 (52.80,65.70) | 0.008 |
| Glucose (mmol/L; normal range 3.89–5.83) | 4.64 (4.28,6.94) | 4.55 (4.17,5.28) | 0.287 |
| Infection-related biomarkers | |||
| C-reactive protein (mg/L; normal range 0.00–10.00) | 1.14 (0.50,4.56) | 0.89 (0.23,1.92) | 0.112 |
| PLR | 133.10(99.10,151.22) | 129.50 (97.70,167.90) | 0.905 |
| NLR | 2.10 (1.60,3.00) | 1.94 (1.55,2.80) | 0.411 |
| LMR | 4.17 (3.15,5.11) | 5.42 (3.49,7.02) | 0.069 |
| Nucleic acid qPCR test | |||
| Nucleic acid positive duration | 14.00 (7.00,25.00) | 12.00 (5.00,24.00) | 0.749 |
| Redetected qPCR+ | 3 (8.82) | 5 (11.11) | 1.000 |
| Incubation period | 8.00 (5.00,12.00) | ||
| Treatment | |||
| TraditionalChinese medicine | 34 (100.00) | 45 (100.00) | |
| antiviral therapy | 32 (94.12) | 38 (84.44) | 0.286 |
Data are presented as median (IQR) or n (%); *P < 0.05 vs. the symptomatic group; IQR: interquartile ranges; COVID-19: novel coronavirus disease 2019; CT: computed tomography; qPCR: quantitative polymerase chain reaction; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio.